Insight Molecular Diagnostics INC. (IMDX) — 8-K Filings

8-K Filings (24)

• Insight Molecular Diagnostics Files 8-K — Nov 10, 2025 Risk: low
  Insight Molecular Diagnostics Inc. filed an 8-K on November 10, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial State
• Insight Molecular Diagnostics Inc. Files 8-K on Officer/Director Changes — Oct 2, 2025 Risk: medium
  Insight Molecular Diagnostics Inc. filed an 8-K on October 2, 2025, reporting events as of September 28, 2025. The filing primarily concerns the departure of di
• Insight Molecular Diagnostics Inc. Announces Board and Officer Changes — Sep 19, 2025 Risk: low
  Insight Molecular Diagnostics Inc. announced on September 16, 2025, changes in its board and officer composition, including the election of new directors and ap
• Insight Molecular Diagnostics Files 8-K — Aug 11, 2025 Risk: low
  Insight Molecular Diagnostics Inc. filed an 8-K on August 11, 2025, reporting on its Results of Operations and Financial Condition. The filing also includes Fin
• Insight Molecular Diagnostics Inc. Files 8-K on Shareholder Vote — Jul 2, 2025 Risk: low
  Insight Molecular Diagnostics Inc. filed an 8-K on July 2, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 27, 20
• Oncocyte Corp. Files 8-K with Corporate Updates — Jun 17, 2025 Risk: low
  On June 13, 2025, Oncocyte Corp. filed an 8-K report detailing amendments to its Articles of Incorporation and Bylaws, along with Regulation FD disclosures and
• Oncocyte Corp Files 8-K on Financials — May 12, 2025 Risk: low
  On May 12, 2025, Oncocyte Corporation filed an 8-K report. The filing pertains to the company's results of operations and financial condition, as well as financ
• Oncocyte Corp Changes Independent Accountant — Apr 17, 2025 Risk: medium
  Oncocyte Corporation announced on April 11, 2025, a change in its certifying accountant. The company has dismissed its previous independent registered public ac
• Oncocyte Corp Files 8-K on Financials — Mar 24, 2025 Risk: low
  On March 24, 2025, Oncocyte Corporation filed an 8-K report detailing results of operations and financial condition. The filing includes financial statements an
• Oncocyte Corp Appoints New Directors, Updates Executive Contracts — Mar 10, 2025 Risk: medium
  On March 4, 2025, Oncocyte Corporation announced changes in its board of directors and executive compensation. Specifically, the company elected two new directo
• Oncocyte Corp Files 8-K: Agreements, Sales, and Disclosures — Feb 10, 2025 Risk: medium
  On February 6, 2025, Oncocyte Corporation entered into a material definitive agreement and simultaneously terminated a prior material definitive agreement. The
• Oncocyte Corp Enters Material Definitive Agreement — Jan 8, 2025 Risk: medium
  On January 2, 2025, Oncocyte Corporation entered into a material definitive agreement. The filing does not provide specific details about the agreement or any a
• Oncocyte Corp Files 8-K on Financials — Nov 12, 2024 Risk: low
  On November 12, 2024, Oncocyte Corporation filed an 8-K report detailing results of operations and financial condition. The filing includes financial statements
• Oncocyte Corp Files 8-K on Director Changes & Compensation — Oct 15, 2024 Risk: medium
  On October 11, 2024, Oncocyte Corporation filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing al
• Oncocyte Corp Files 8-K: Material Agreement, Equity Sales — Oct 3, 2024 Risk: medium
  On October 2, 2024, Oncocyte Corporation entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company
• Oncocyte Corp Files 8-K: Material Agreements Entered and Terminated — Aug 9, 2024 Risk: medium
  On August 9, 2024, Oncocyte Corporation entered into a Material Definitive Agreement and also terminated a Material Definitive Agreement. The filing does not pr
• Oncocyte Corp Faces Delisting Concerns — Jul 12, 2024 Risk: high
  Oncocyte Corporation filed an 8-K on July 12, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest eve
• Oncocyte Corp to be Acquired — Jul 5, 2024 Risk: medium
  Oncocyte Corporation announced on June 28, 2024, that it has entered into a definitive agreement to be acquired by a third party. The company also reported on t
• Oncocyte Corp Files 8-K: Board & Executive Changes — Jun 17, 2024 Risk: medium
  On June 17, 2024, Oncocyte Corporation filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the depa
• Oncocyte Corp Elects New Directors, Reports Executive Compensation — May 31, 2024 Risk: medium
  On May 30, 2024, Oncocyte Corporation announced the election of Dr. Jonathan P. S. Farber and Mr. David E. Bear to its Board of Directors. Additionally, the com
• Oncocyte Corp Appoints New Directors, Reports Executive Compensation — May 23, 2024 Risk: medium
  On May 20, 2024, Oncocyte Corporation announced the election of Dr. Michael J. McShane and Mr. David L. Briones to its Board of Directors. Additionally, the com
• Oncocyte Corp Files 8-K: Material Agreement, Financials, Equity Sales — Apr 12, 2024 Risk: medium
  On April 11, 2024, Oncocyte Corporation entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company also report
• Oncocyte Corp Files 8-K: Material Agreement & Financials — Apr 11, 2024 Risk: medium
  On April 5, 2024, Oncocyte Corporation entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company also reporte
• Oncocyte Files 8-K for Jan 22 Event; Routine Disclosure — Jan 23, 2024
  Oncocyte Corporation filed an 8-K on January 23, 2024, reporting an event that occurred on January 22, 2024. This filing is a routine disclosure under Regulatio

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX